The ordinance authorizes a partial settlement of a lawsuit against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, for $6 million to $11 million over nine years due to their role in the opioid crisis. The lawsuit alleges that they created a public nuisance and violated laws through deceptive marketing and distribution of opioids in San Francisco.
Ordinance authorizing the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., for abatement funds in the range of $6 million to $11 million to be paid over 9 years; the lawsuit was filed on December 18, 2018, in the United States District Court for the Northern District of California, Case No. 3:18-cv-7591-CRB-JSC; entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; the lawsuit involves allegations that Johnson and Johnson’s subsidiary, Janssen Pharmaceuticals, Inc., created a public nuisance and violated the Unfair Competition Law and the False Advertising Laws through deceptive marketing of opioids, manufacturing and distributing increasingly large volumes of opioids in and around San Francisco despite knowledge of the growing epidemic caused by opioid misuse, and by failing to prevent and to report suspicious opioid orders as required by state and federal law.
How it got here
This legislation originated from a lawsuit filed by the City and County of San Francisco against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, regarding opioid-related public nuisance claims.
The City and County of San Francisco filed a lawsuit against multiple pharmaceutical companies, including Johnson & Johnson and Janssen Pharmaceuticals, in the United States District Court for the Northern District of California.
The City Attorney prepared an ordinance to authorize the partial settlement of the lawsuit, estimating abatement funds between $6 million and $11 million to be paid over 9 years.
The Board of Supervisors passed the ordinance on first reading, allowing the City Attorney to proceed with the settlement.
The Board of Supervisors finally passed the ordinance, officially authorizing the settlement with Johnson & Johnson.
The Mayor approved the ordinance, finalizing the settlement agreement with Johnson & Johnson.
Reconstructed from attached documents & the official record
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
The motion endorses a settlement in a lawsuit against major distributors of prescription opioids, aimed at addressing the opioid crisis in San Francisco. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The legislation involves a public hearing to discuss proposed ordinances related to a partial settlement of lawsuits against major opioid distributors and manufacturers, seeking abatement funds totaling between $33 million and $61 million over several years. This hearing is scheduled for November 2, 2021, at 3:00 p.m.
This legislation allows the San Francisco Board of Supervisors to hold a closed session to discuss legal advice regarding ongoing lawsuits against major opioid distributors and manufacturers, seeking settlement funds for the city. The lawsuits aim to secure between $27 million to $50 million and $6 million to $11 million in abatement funds to address the opioid crisis over specified timeframes.
The motion endorses a settlement in a lawsuit against major distributors of prescription opioids, aimed at addressing the opioid crisis in San Francisco. It also schedules a public hearing and a closed session for the Board of Supervisors to discuss the litigation with the City Attorney.
